Themis Medicare (BSE:530199) - Share price, News & Analysis

530199 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	6/6
Financial Health	6/6
Dividends	3/6

530199 Stock Overview

Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally.

Rewards

Trading at 18.7% below our estimate of its fair value

Earnings grew by 103.2% over the past year

Risk Analysis

Unstable dividend track record

Themis Medicare Competitors

Cipla

NSEI:CIPLA

₹789.4b

Krebs Biochemicals & Industries

BSE:524518

₹2.8b

Gennex Laboratories

BSE:531739

₹884.3m

Oxygenta Pharmaceutical

BSE:524636

₹356.5m

Price History & Performance

Summary of all time highs, changes and price drops for Themis Medicare
Historical stock prices
Current Share Price	₹882.15
52 Week High	₹1,198.80
52 Week Low	₹486.95
Beta	1.08
1 Month Change	-5.75%
3 Month Change	-17.83%
1 Year Change	78.39%
3 Year Change	239.22%
5 Year Change	66.33%
Change since IPO	3,918.91%

Shareholder Returns

	530199	IN Pharmaceuticals	IN Market
7D	7.3%	3.5%	3.4%
1Y	78.4%	-9.6%	9.6%

Return vs Industry: 530199 exceeded the Indian Pharmaceuticals industry which returned -9.6% over the past year.

Return vs Market: 530199 exceeded the Indian Market which returned 9.6% over the past year.

Price Volatility

Is 530199's price volatile compared to industry and market?
530199 volatility
530199 Average Weekly Movement	5.5%
Pharmaceuticals Industry Average Movement	7.0%
Market Average Movement	7.3%
10% most volatile stocks in IN Market	10.0%
10% least volatile stocks in IN Market	4.8%

Stable Share Price: 530199 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 530199's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1969	976	Sachin Patel	https://www.themismedicare.com

Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations for use in various therapeutic areas, including anti-infective, antimalarial, anti-tuberculosis, cardiology, health and nutrition, oncology, ophthalmology, and pain management. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001.

Themis Medicare Fundamentals Summary

How do Themis Medicare's earnings and revenue compare to its market cap?
530199 fundamental statistics
Market Cap	₹8.12b
Earnings (TTM)	₹709.84m
Revenue (TTM)	₹3.77b

11.4x

P/E Ratio

2.2x

P/S Ratio

Is 530199 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
530199 income statement (TTM)
Revenue	₹3.77b
Cost of Revenue	₹1.44b
Gross Profit	₹2.33b
Other Expenses	₹1.62b
Earnings	₹709.84m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 30, 2022

Earnings per share (EPS)	77.15
Gross Margin	61.83%
Net Profit Margin	18.85%
Debt/Equity Ratio	25.2%

How did 530199 perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

6%

Payout Ratio

Valuation

Is Themis Medicare undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

18.7%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: 530199 (₹882.15) is trading below our estimate of fair value (₹1085.52)

Significantly Below Fair Value: 530199 is trading below fair value, but not by a significant amount.

Price To Earnings Ratio

PE vs Industry: 530199 is good value based on its PE Ratio (11.4x) compared to the Indian Pharmaceuticals industry average (21.9x).

PE vs Market: 530199 is good value based on its PE Ratio (11.4x) compared to the Indian market (20.5x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 530199's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 530199 is overvalued based on its PB Ratio (3.1x) compared to the IN Pharmaceuticals industry average (2.6x).

Future Growth

How is Themis Medicare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

22.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Themis Medicare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Themis Medicare performed over the past 5 years?

Past Performance Score

6/6

Past Performance Score 6/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

41.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 530199 has high quality earnings.

Growing Profit Margin: 530199's current net profit margins (18.8%) are higher than last year (16.2%).

Past Earnings Growth Analysis

Earnings Trend: 530199's earnings have grown significantly by 41.5% per year over the past 5 years.

Accelerating Growth: 530199's earnings growth over the past year (103.2%) exceeds its 5-year average (41.5% per year).

Earnings vs Industry: 530199 earnings growth over the past year (103.2%) exceeded the Pharmaceuticals industry 12.4%.

Return on Equity

High ROE: 530199's Return on Equity (26.8%) is considered high.

Financial Health

How is Themis Medicare's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: 530199's short term assets (₹2.1B) exceed its short term liabilities (₹1.1B).

Long Term Liabilities: 530199's short term assets (₹2.1B) exceed its long term liabilities (₹260.6M).

Debt to Equity History and Analysis

Debt Level: 530199's net debt to equity ratio (15.5%) is considered satisfactory.

Reducing Debt: 530199's debt to equity ratio has reduced from 89.4% to 25.2% over the past 5 years.

Debt Coverage: 530199's debt is well covered by operating cash flow (85.3%).

Interest Coverage: 530199's interest payments on its debt are well covered by EBIT (14.4x coverage).

Balance Sheet

Dividend

What is Themis Medicare current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

0.49%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 530199's dividend (0.49%) is higher than the bottom 25% of dividend payers in the Indian market (0.35%).

High Dividend: 530199's dividend (0.49%) is low compared to the top 25% of dividend payers in the Indian market (1.59%).

Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 530199 has been paying a dividend for less than 10 years.

Growing Dividend: 530199's dividend payments have increased, but the company has only paid a dividend for 2 years.

Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (5.6%), 530199's dividend payments are thoroughly covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (10%), 530199's dividend payments are thoroughly covered by cash flows.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure

CEO

Sachin Patel (46 yo)

5.25yrs

Tenure

₹6,703,200

Compensation

Dr. Sachin Dinesh Patel, Ph D., CChem. has been Chief Executive Officer and Managing Director of Themis Medicare Limited since February 14, 2017.He served as Deputy Managing Director at Themis Medicare Lt...

CEO Compensation Analysis

Compensation vs Market: Sachin's total compensation ($USD86.15K) is above average for companies of similar size in the Indian market ($USD38.72K).

Compensation vs Earnings: Sachin's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: 530199's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Experienced Board: 530199's board of directors are considered experienced (8.3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/21 00:00
End of Day Share Price	2022/05/20 00:00
Earnings	2021/12/31
Annual Earnings	2021/03/31